Other languages Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
11.94 ^USD	+0.59%		+8.25%	+127.00%

07/05	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating	MT
06/05	Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Stoke Therapeutics Appoints Thomas Leggett CFO	29/04
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	17/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Stoke Therapeutics Plans $75 Million Public Offering	27/03
MÄRKTE USA/Etwas leichter - Zurückhaltung vor Inflationsdaten	27/03
Sector Update: Health Care Stocks Advance Late Afternoon	27/03
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients	27/03
Top Midday Gainers	26/03
MÄRKTE USA/Gut behauptet - Hoffen auf Inflationsdaten	26/03
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26/03
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	26/03
Top Premarket Gainers	26/03
MÄRKTE USA/Etwas fester - Hoffen auf Preisdaten	26/03
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Stoke Therapeutics, Inc Announces New Data that Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome	26/03
Stoke Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
Stoke Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors	21/23/21
Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Other languages

Filters